Merck stops testing combo drug for lung cancer
Adds details in paragraphs 2 and 6, background throughout
Aug 8 (Reuters) -Merck MRK.N said on Thursday it had discontinued a trial testing a combination immunotherapy treatmentin patients with a type of lung cancer after an interim analysis showed the drug was unlikely to succeed.
The patients tested with a combination of its experimentaldrug, vibostolimab, with Keytruda experienced a higher rate of immune-related side effects, Merck said, adding that patients should stop ongoing treatment with the therapy.
The discontinuation marked yet another setback for vibostolimab and the promising new class of immunotherapies called anti-TIGIT to which it belongs.
Gilead Sciences GILD.O, Roche ROG.S and GSK GSK.L are among half a dozen drugmakers looking to grab a share of the lucrative anti-TIGIT cancer drug market, but the field has experienced multiplesetbacks.
Vibostolimab works by selectively binding itself to TIGIT, a receptor on immune cells, to activate the immune system against cancer cells and prevent a misguided immune attack against healthy cells.
Merck was testing vibostolimab along with Keytruda as a first-line treatment for patientswith extensive-stage small cell lung cancer in the late-stage study.
Last year, the combination therapy had failed to significantly slow disease progression in lung cancer patients who did not respond to previous treatments.
The drugmakerdiscontinued another late-stage study in May testing the combination therapy in patients with a severe form of skin cancer after side effects led to high discontinuation.
Reporting by Leroy Leo in Bengaluru; Editing by Devika Syamnath
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
